Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BY 4.0NPJ Vaccines

The immunogenicity of pneumococcal conjugate vaccinations in patients with asplenia and hyposplenia: a systematic review

  • B. van Put1
  • G. E. Loe-Sack-Sioe1,2
  • L. G. Visser1
  • S. P. Jochems2
  • A. H. E. Roukens1
  • H. Jolink1
  1. 1Subdepartment of Infectious Diseases, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands
  2. 2Subdepartment of Research, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands
Read full textPDFDOICite

Abstract

Pneumococcal conjugate vaccines (PCVs) are important preventive tools against invasive pneumococcal disease (IPD) in asplenic patients. This systematic review assesses current data and knowledge gaps on the immunogenicity of PCVs in asplenic patients. Twenty-seven studies were included assessing post-PCV IgG, opsonophagocytic functionality (OPA), or B-cell responses. We show that PCVs induce a strong serotype-specific IgG and OPA response in asplenic adults and children with various underlying conditions. Data in this review suggest that PPV23 has limited benefits for adults, but has been shown to broaden and boost the vaccine response in children with sickle cell disease. Moreover, we detected a lack of data on B-cell responses post-PCV and the optimal timing for vaccination around splenectomy. In conclusion, administration of PCVs in asplenic patients is supported by this review. The role of PPV23 in asplenic adults is probably limited, which supports the expected replacement of PPV23 by higher valent PCVs.

Related

  1. Immunogenicity of sequential conjugate and non-conjugate pneumococcal vaccination in dialysis patients and kidney transplant recipients: a 12-month serological follow-up
    Sophie Novelli, Aimé Nun, Antoine Cases +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  2. Comparative Efficacy and Safety of 15-Valent and 13-Valent Pneumococcal Conjugate Vaccines Alone and in Combination with the 23-Valent Polysaccharide Vaccine: A Systematic Review and Meta-analysis
    Yuri Matsumoto, Takayuki Mihara, Yuko Okamoto +11
    Biological and Pharmaceutical BulletinPeer-reviewedCC BY-NCFull textEpidemiology & public healthJ-STAGE
  3. Cost-effectiveness of 20-valent versus 15-valent pneumococcal conjugate vaccines for infants in the Netherlands, taking into account indirect effects and adult vaccination
    Pieter T. de Boer, Albert Jan van Hoek, Mirjam Knol +4
    BMC MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine.
    Joon Young Song, Ki Tae Kwon, Wan Beom Park +8
    Infection & chemotherapyPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  5. Antimicrobial resistance trends and lineage distribution among invasive pneumococcal disease isolates pre- and post-pneumococcal conjugate vaccine introduction, South Africa
    Cebile Lekhuleni, Kedibone Ndlangisa, Linda de Gouveia +17
    Journal of InfectionPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ

Cite

BibTeXRIS
BibTeX
@article{put2026immunogenicity,
  title = {{The immunogenicity of pneumococcal conjugate vaccinations in patients with asplenia and hyposplenia: a systematic review}},
  author = {B. van Put and G. E. Loe-Sack-Sioe and L. G. Visser and S. P. Jochems and A. H. E. Roukens and H. Jolink},
  journal = {NPJ Vaccines},
  year = {2026},
  month = jul,
  doi = {10.1038/s41541-026-01514-9},
  url = {https://doi.org/10.1038/s41541-026-01514-9},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The immunogenicity of pneumococcal conjugate vaccinations in patients with asplenia and hyposplenia: a systematic review
AU  - B. van Put
AU  - G. E. Loe-Sack-Sioe
AU  - L. G. Visser
AU  - S. P. Jochems
AU  - A. H. E. Roukens
AU  - H. Jolink
PY  - 2026
DA  - 2026/07/06
JO  - NPJ Vaccines
DO  - 10.1038/s41541-026-01514-9
UR  - https://doi.org/10.1038/s41541-026-01514-9
AB  - Pneumococcal conjugate vaccines (PCVs) are important preventive tools against invasive pneumococcal disease (IPD) in asplenic patients. This systematic review assesses current data and knowledge gaps on the immunogenicity of PCVs in asplenic patients. Twenty-seven studies were included assessing post-PCV IgG, opsonophagocytic functionality (OPA), or B-cell responses. We show that PCVs induce a strong serotype-specific IgG and OPA response in asplenic adults and children with various underlying conditions. Data in this review suggest that PPV23 has limited benefits for adults, but has been shown to broaden and boost the vaccine response in children with sickle cell disease. Moreover, we detected a lack of data on B-cell responses post-PCV and the optimal timing for vaccination around splenectomy. In conclusion, administration of PCVs in asplenic patients is supported by this review. The role of PPV23 in asplenic adults is probably limited, which supports the expected replacement of PPV23 by higher valent PCVs.
SN  - 2059-0105
ER  -